Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ultragenyx Pharmaceutical's other long-term liabilities for the quarter that ended in Jun. 2026 was MXN20,363 Mil.
Ultragenyx Pharmaceutical's quarterly other long-term liabilities
increased
from Dec. 2025 (MXN21,013 Mil) to Mar. 2026 (MXN21,098 Mil) but then
declined
from Mar. 2026 (MXN21,098 Mil) to Jun. 2026 (MXN20,363 Mil).
Ultragenyx Pharmaceutical's annual other long-term liabilities
increased
from Dec. 2023 (MXN14,844 Mil) to Dec. 2024 (MXN17,456 Mil) and
increased
from Dec. 2024 (MXN17,456 Mil) to Dec. 2025 (MXN21,013 Mil).
Ultragenyx Pharmaceutical Other Long-Term Liabilities Related Terms
Ultragenyx Pharmaceutical Other Long-Term Liabilities Historical Data
* Premium members only.
The historical data trend for Ultragenyx Pharmaceutical's Other Long-Term Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical Other Long-Term Liabilities Chart
Ultragenyx Pharmaceutical Other Long-Term Liabilities Calculation
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
What does a Other Long-Term Liabilities of MXN20,363 Mil mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a Other Long-Term Liabilities of MXN20,363 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Other Long-Term Liabilities too high?
Ultragenyx Pharmaceutical's current Other Long-Term Liabilities is MXN20,363 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Other Long-Term Liabilities compare to PGEN and PHVS?
Ultragenyx Pharmaceutical's Other Long-Term Liabilities of MXN20,363 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Other Long-Term Liabilities is MXN20,363 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (MEX:RARE) is currently considered Possible Value Trap. The stock's GF Value™ is MXN767.63, compared to a current price of MXN450.00 — trading 41.4% below its estimated fair value. The current Other Long-Term Liabilities is MXN20,363 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Other Long-Term Liabilities is MXN20,363 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of MXN450.00 is trading 41.4% below its estimated GF Value™ of MXN767.63.
GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.
Key valuation signals for MEX:RARE:
Other Long-Term Liabilities: MXN20,363 Mil
GF Value™: MXN767.63 vs. price of MXN450.00 (41.4% below fair value)
No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
64GF Score
Get the complete analysis for MEX:RARE
Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RARE has been successfully added to your 
